Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $30 million, in a deal that lets the beleaguered Somerville-based biotech avoid bankruptcy.
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
Bluebird Bio, Inc. (NASDAQ:BLUE), on Friday, entered into a definitive agreement to be acquired by global investment firms ...
(Reuters) -Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle Group and SK Capital Partners at a ...
Herrington & Sutcliffe are serving as legal advisors to Carlyle and SK Capital. About bluebird bio, Inc. Founded in 2010, bluebird has been setting the standard for gene therapy for more than ...
Baird analyst Jack Allen downgraded Bluebird Bio (BLUE) to Neutral from Outperform with a price target of $5, down from $54, after the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback